CD19 and non-Hodgkin lymphoma: In recent years, anti-CD19 CAR-T cell therapy has achieved rapid and durable responses in patients with R/R B-ALL and NHL (1–6, 16), and has dramatically altered the therapeutic landscape of B cell malignancies.